ADIL

$1.89

Post-MarketAs of Mar 17, 8:00 PM UTC

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.89
Potential Upside
5%
Whystock Fair Value$1.98
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, whic...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.70M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.32
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-170.73%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
4.21

Recent News

Zacks
Jan 6, 2026

Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?

Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
The Fly
Sep 30, 2025

CoreWeave initiated, Instacart downgraded: Wall Street's top analyst calls

CoreWeave initiated, Instacart downgraded: Wall Street's top analyst calls

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Benzinga
Sep 16, 2025

Adial Pharmaceuticals Highlights Favorable Comments From FDA Meeting For Lead Program In Alcohol Use Disorder

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) on Tuesday received the final meeting minutes from its End of Phase 2 (EOP2) Meeting with the U.S. Food and Drug Administration (FDA) held in July. The minutes provide the FDA's formal input into the AD04 Phase 3 adaptive clinical trial design and broader clinical development strategy. The objective for the EOP2 Meeting was to align with the FDA on the design of the Phase 3 clinical development program for AD04, the company's lead investigational drug, a

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Sep 1, 2025

All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy

Adial Pharmaceuticals (ADIL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Jul 15, 2025

Thermo Fisher Scientific (TMO) Inks Deal to Manufacture Adial Pharmaceuticals ADO4

Thermo Fisher Scientific Inc. (NYSE:TMO) is one of Goldman Sachs’ top healthcare stock picks. On June 25, the company confirmed it had inked a strategic partnership with Adial Pharmaceuticals (NASDAQ:ADIL). Under the terms of the agreement, Thermo Fisher is to become the Contract Development and Manufacturing Organization (CDMO) for AD04 Drug products. The product is […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.